- Home
- RDNW vs ACHV Comparison
RDNW vs ACHV Comparison
Compare RDNW & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDNW
- ACHV
- Stock Information
- Founded
- RDNW 2013
- ACHV N/A
- Country
- RDNW United States
- ACHV United States
- Employees
- RDNW N/A
- ACHV N/A
- Industry
- RDNW EDP Services
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RDNW Technology
- ACHV Health Care
- Exchange
- RDNW Nasdaq
- ACHV Nasdaq
- Market Cap
- RDNW 147.3M
- ACHV 153.8M
- IPO Year
- RDNW N/A
- ACHV N/A
- Fundamental
- Price
- RDNW $4.22
- ACHV $3.18
- Analyst Decision
- RDNW
- ACHV Strong Buy
- Analyst Count
- RDNW 0
- ACHV 2
- Target Price
- RDNW N/A
- ACHV $16.00
- AVG Volume (30 Days)
- RDNW 44.5K
- ACHV 867.2K
- Earning Date
- RDNW 11-11-2025
- ACHV 11-06-2025
- Dividend Yield
- RDNW N/A
- ACHV N/A
- EPS Growth
- RDNW N/A
- ACHV N/A
- EPS
- RDNW N/A
- ACHV N/A
- Revenue
- RDNW $1,109,200,000.00
- ACHV N/A
- Revenue This Year
- RDNW N/A
- ACHV N/A
- Revenue Next Year
- RDNW $7.73
- ACHV N/A
- P/E Ratio
- RDNW N/A
- ACHV N/A
- Revenue Growth
- RDNW N/A
- ACHV N/A
- 52 Week Low
- RDNW $1.46
- ACHV $1.84
- 52 Week High
- RDNW $7.06
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- RDNW N/A
- ACHV 57.72
- Support Level
- RDNW N/A
- ACHV $3.07
- Resistance Level
- RDNW N/A
- ACHV $3.26
- Average True Range (ATR)
- RDNW 0.00
- ACHV 0.15
- MACD
- RDNW 0.00
- ACHV 0.01
- Stochastic Oscillator
- RDNW 0.00
- ACHV 82.65
About RDNW RideNow Group Inc. Class B Common Stock
RideNow Group Inc is a USA-based online retailer that allows consumers and dealers both to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.